News
Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...
Walmart’s adjusted earnings miss analysts’ estimates but second-quarter revenue tops forecasts. Tech stocks Palantir, Nvidia, ...
Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback